 Nuformix PLC LSE:NFX said Oxilio has signed a service contract to support the formulation development of NXP-001, which the latter has licensed from the former. Oxilio in turn is working with Quotient NASDAQ:QTNT Sciences, a drug development and manufacturing accelerator. 